Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Public ClinicalTrials.gov record NCT01728324. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Randomised, Partially Double-blind and Placebo-controlled Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Chronic Genotype 1 Hepatitis C Infection in an Extended Population of Treatment naïve Patients That Includes Those Ineligible to Receive Peginterferon
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The aim of the study is to confirm efficacy and safety of treatment with 600 mg of BID BI 207127 in combination with 120 mg QD FDV and RBV for 16 or 24 weeks in target chronically infected HCV GT1b treatment naïve patients, including patients with compensated cirrhosis.
Study identification
- NCT ID
- NCT01728324
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 496 participants
Conditions and interventions
Conditions
Interventions
- BI 207127-placebo: 8-week treatment Drug
- Ribavirin: 24-week treatment Drug
- BI 207127: 24-week treatment Drug
- Faldaprevir: 24-week treatment Drug
- Ribavirin-placebo: 8-week treatment Drug
- Faldaprevir-placebo: 8-week treatment Drug
- Faldaprevir: 16-week treatment Drug
- Ribavirin: 16-week treatment Drug
- RBV: 24-week treatment Drug
- BI 207127: 16-week treatment Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2012 (Type not available)
- Primary completion
- Feb 2014 (Actual)
- Completion
- Jan 2015 (Actual)
- Last update posted
- Feb 12, 2016
2012 – 2015
United States locations
- U.S. sites
- 31
- U.S. states
- 13
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1241.36.00016 Boehringer Ingelheim Investigational Site | North Little Rock | Arkansas | — | — |
| 1241.36.00020 Boehringer Ingelheim Investigational Site | Anaheim | California | — | — |
| 1241.36.00005 Boehringer Ingelheim Investigational Site | Bakersfield | California | — | — |
| 1241.36.00009 Boehringer Ingelheim Investigational Site | La Jolla | California | — | — |
| 1241.36.00007 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 1241.36.00013 Boehringer Ingelheim Investigational Site | Oceanside | California | — | — |
| 1241.36.00019 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 1241.36.00034 Boehringer Ingelheim Investigational Site | San Francisco | California | — | — |
| 1241.36.00022 Boehringer Ingelheim Investigational Site | Bradenton | Florida | — | — |
| 1241.36.00004 Boehringer Ingelheim Investigational Site | DeLand | Florida | — | — |
| 1241.36.00006 Boehringer Ingelheim Investigational Site | Fort Lauderdale | Florida | — | — |
| 1241.36.00003 Boehringer Ingelheim Investigational Site | Gainesville | Florida | — | — |
| 1241.36.00010 Boehringer Ingelheim Investigational Site | Orlando | Florida | — | — |
| 1241.36.00024 Boehringer Ingelheim Investigational Site | Palm Harbor | Florida | — | — |
| 1241.36.00030 Boehringer Ingelheim Investigational Site | Zephyrhills | Florida | — | — |
| 1241.36.00027 Boehringer Ingelheim Investigational Site | Atlanta | Georgia | — | — |
| 1241.36.00033 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 1241.36.00035 Boehringer Ingelheim Investigational Site | Springfield | Illinois | — | — |
| 1241.36.00001 Boehringer Ingelheim Investigational Site | Valparaiso | Indiana | — | — |
| 1241.36.00017 Boehringer Ingelheim Investigational Site | Baton Rouge | Louisiana | — | — |
| 1241.36.00018 Boehringer Ingelheim Investigational Site | Tupelo | Mississippi | — | — |
| 1241.36.00043 Boehringer Ingelheim Investigational Site | Kansas City | Missouri | — | — |
| 1241.36.00032 Boehringer Ingelheim Investigational Site | Hillsborough | New Jersey | — | — |
| 1241.36.00002 Boehringer Ingelheim Investigational Site | Arlington | Texas | — | — |
| 1241.36.00039 Boehringer Ingelheim Investigational Site | Austin | Texas | — | — |
| 1241.36.00031 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 1241.36.00008 Boehringer Ingelheim Investigational Site | Murray | Utah | — | — |
| 1241.36.00026 Boehringer Ingelheim Investigational Site | Charlottesville | Virginia | — | — |
| 1241.36.00044 Boehringer Ingelheim Investigational Site | Newport News | Virginia | — | — |
| 1241.36.00015 Boehringer Ingelheim Investigational Site | Norfolk | Virginia | — | — |
| 1241.36.00029 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 78 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01728324, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 12, 2016 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01728324 live on ClinicalTrials.gov.